Background: Adiponectin is an anti-inflammatory and potentially anti-atherogenic molecule. Some recent reports suggest that TNFα blockade therapy increases circulating adiponectin levels but data are sparse and inconsistent.
Methods: Data from a double-blind placebo-controlled study of onercept in 126 psoriatic arthritis patients (PsA) and data from pre- and post adalimumab treatment in 171 rheumatoid arthritis (RA) patients were used to examine the effect of TNFα blockade therapy on adiponectin.
Results: Despite expected associations of adiponectin to gender and baseline HDL-cholesterol and triglyceride, adiponectin levels did not change over time with TNFα blockade therapy in either group. Absolute change in adiponectin levels were -0.23 ±4.6μg/ml in onercept 50mg and onercept 100mg combined group (versus placebo, p=0.60) in PsA patients and 0.28 ±3.23μg/ml (p=0.66 versus baseline) in RA patients treated with adalimumab.
Discussion: These results go against a significant effect of TNFα blockade therapy on circulating adiponectin levels in patients with autoimmune disease.